TSX:HBP - Toronto Stock Exchange - CA4229102088 - Common Stock - Currency: CAD
HELIX BIOPHARMA CORP
TSX:HBP (2/3/2025, 7:00:00 PM)
0.9
-0.02 (-2.17%)
The current stock price of HBP.CA is 0.9 CAD. In the past month the price decreased by -10%. In the past year, price decreased by -10%.
VANCOUVER, BC / ACCESSWIRE / April 22, 2022 / Mr. Jerzy Wilczewski announces the acquisition of 7,700,000 common shares ("Common Shares") in the capital of Helix Biopharma Corp. ("Helix" or the "Company") (TSX: HBP) at a price of $0.26 per Common Share by way of non-brokered private placement for an aggregate subscription price of C$2,002,000 (the "Private Placement"). As a result of the closing of the Private Placement, Mr. Wilczewski
RICHMOND HILL, ON / ACCESSWIRE / April 21, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has closed a private placement financing for net proceeds of $2,002,000 from the issuance of 7,700,000 common shares at a price of $0.26 per common
RICHMOND HILL, ON / ACCESSWIRE / December 15, 2021 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced fiscal 2022 first quarter results for the period ending October 31, 2021. OVERVIEW The Company reported a net loss and total comprehensive loss for the
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 247.78M | ||
BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 236.47M | ||
EDT.CA | SPECTRAL MEDICAL INC | N/A | 166.88M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 163.85M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 105.75M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 99.26M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 28.09 | 84.67M | ||
ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 84.01M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 79.27M | ||
MBX.CA | MICROBIX BIOSYSTEMS INC | 16.5 | 66.59M | ||
SVA.CA | SERNOVA CORP | N/A | 55.07M | ||
MDCX.CA | MEDICUS PHARMA LTD | N/A | 41.77M |
Helix BioPharma Corp is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 7 full-time employees. Helix BioPharma Corp. is a clinical-stage biopharmaceutical company. The firm is focused on developing therapies in the field of immune oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. DOS47 is a broad anti-cancer antibody drug conjugate (ADC) platform. DOS47 is based upon a naturally occurring enzyme isolated from the jack bean plant called urease that breaks down a natural substance found in the body, urea, into metabolites that include ammonium and hydroxyl ions. By doing so at the site of cancerous tissues in the body, DOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extracellular conditions that are believed to act to defend the tumor. Its pipeline includes L-DOS47 monotherapy NSCLC, L-DOS47 combo PEM/CARBO NSCLC, L-DOS47 DOXO combo Pancreas, and L-DOS47 combo Immune Checkpoints.
HELIX BIOPHARMA CORP
Bay Adelaide Centre - North Tower 40, Temperance Street, Suite 2700 Toronto
TORONTO ONTARIO L4B 3J9 CA
CEO: Heman Chao
Employees: 9
Company Website: https://www.helixbiopharma.com/
Investor Relations: http://www.helixbiopharma.com/investor-relations/
Phone: 16046842181
The current stock price of HBP.CA is 0.9 CAD.
The exchange symbol of HELIX BIOPHARMA CORP is HBP and it is listed on the Toronto Stock Exchange exchange.
HBP.CA stock is listed on the Toronto Stock Exchange exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for HBP.CA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of HBP.CA.
HBP.CA does not pay a dividend.
HBP.CA does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.19).
ChartMill assigns a technical rating of 2 / 10 to HBP.CA. When comparing the yearly performance of all stocks, HBP.CA turns out to be only a medium performer in the overall market: it outperformed 41.3% of all stocks.
Over the last trailing twelve months HBP.CA reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS decreased by -215.04% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -2257.73% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to HBP.CA. The Buy consensus is the average rating of analysts ratings from 5 analysts.